Jeffrey M.  Leiden net worth and biography

Jeffrey Leiden Biography and Net Worth

Dr. Leiden is the Executive Chairman of Vertex Pharmaceuticals. He received his B.A., M.D. and Ph.D. degrees with honors from the University of Chicago. He is a physician and scientist who, for the last 40 years, has dedicated his career to improving the lives of people with serious diseases. His experience spans all aspects of the biotech and pharmaceutical industries.

He began his career in academia as a molecular biologist and practicing cardiologist. From 1987 to 2000, Dr. Leiden held several academic and hospital appointments, including roles as Chief of Cardiology, the Rawson Professor of Medicine and Pathology, and an Attending Physician at the University of Chicago; the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health; and Professor of Medicine at Harvard Medical School. Dr. Leiden was named a Crain’s Chicago Business 40 Under 40 in 1994, and served as a member of the National Heart, Lung, and Blood Institute Board of Scientific Counselors from 1994 to 1999. During his academic career, he was also involved in starting several biotechnology companies including Vical and Cardiogene. 

From 2000 to 2006, he served as President and Chief Operating Officer and Chief Scientific Officer at Abbott Laboratories where he had responsibility for running Abbott’s global pharmaceuticals business. While at Abbott, Dr. Leiden led the development and launch of multiple breakthrough medicines, including HUMIRA® (adalimumab) for rheumatoid arthritis and other autoimmune diseases and KALETRA® (lopinavir/ritonavir) for HIV infection.

He also held a number of industry board positions, including as a director of Abbott Laboratories and TAP, non-executive Vice Chairman of Shire Pharmaceuticals Plc and director of Millennium Pharmaceuticals, Inc.   From 2006 to 2011, he was a Managing Director of Clarus Ventures, a life sciences venture capital firm. There he was dedicated to developing new treatments through the creation of innovative biotech companies.

Dr. Leiden has served as a member of Vertex’s board of directors since 2009 and was President and CEO from 2012 to 2020. Under his leadership, Vertex delivered the first and only precision medicines to treat the underlying cause of cystic fibrosis (CF). It is his mission and the basis of the company’s research priorities to bring transformative medicines to people with CF and other serious diseases. Dr. Leiden also cares deeply about inspiring and equipping under-resourced students and young women to become the next generation of scientific leaders. He established a signature program at Vertex to enhance science, technology, engineering, art and math (STEAM) education among students in our local communities, including an on-site Learning Lab, mentorship programs, internships and college scholarships. In 2017, Vertex announced a sustained corporate giving commitment of $500 million over the next 10 years, of which $50 million is focused on STEAM education.

In addition to his responsibilities at Vertex, Dr. Leiden is currently Chairman of Casana, a home health monitoring company, and Chairman of Tmunity Therapeutics, a biotechnology company developing novel T-cell immunotherapies to treat solid tumors. He is Vice Chairman of the Massachusetts Competitive Partnership and a director of the Massachusetts Mutual Life Insurance Company. Dr. Leiden also serves on the board of fellows of Harvard Medical School and as co-chair of Massachusetts Governor Charlie Baker’s STEM Advisory Council and Digital Health Council. He is a fellow of the American Academy of Arts and Sciences and an elected member of the National Academy of Medicine, the American Society of Clinical Investigation and the American Association of Physicians.

What is Jeffrey M. Leiden's net worth?

The estimated net worth of Jeffrey M. Leiden is at least $11.89 million as of February 12th, 2024. Dr. Leiden owns 27,644 shares of Vertex Pharmaceuticals stock worth more than $11,889,961 as of February 26th. This net worth estimate does not reflect any other assets that Dr. Leiden may own. Additionally, Dr. Leiden receives an annual salary of $92,930.00 as Chairman at Vertex Pharmaceuticals. Learn More about Jeffrey M. Leiden's net worth.

How old is Jeffrey M. Leiden?

Dr. Leiden is currently 68 years old. There are 6 older executives and no younger executives at Vertex Pharmaceuticals. Learn More on Jeffrey M. Leiden's age.

What is Jeffrey M. Leiden's salary?

As the Chairman of Vertex Pharmaceuticals Incorporated, Dr. Leiden earns $92,930.00 per year. There are 4 executives that earn more than Dr. Leiden. The highest earning executive at Vertex Pharmaceuticals is Dr. Reshma Kewalramani FASN, M.D., CEO, President & Director, who commands a salary of $5,220,000.00 per year. Learn More on Jeffrey M. Leiden's salary.

How do I contact Jeffrey M. Leiden?

The corporate mailing address for Dr. Leiden and other Vertex Pharmaceuticals executives is 50 NORTHERN AVENUE, BOSTON MA, 02210. Vertex Pharmaceuticals can also be reached via phone at (617) 341-6100 and via email at [email protected]. Learn More on Jeffrey M. Leiden's contact information.

Has Jeffrey M. Leiden been buying or selling shares of Vertex Pharmaceuticals?

Within the last three months, Jeffrey M. Leiden has sold $3,900,195.92 in Vertex Pharmaceuticals stock. Most recently, Jeffrey M. Leiden sold 2,656 shares of the business's stock in a transaction on Monday, February 12th. The shares were sold at an average price of $419.51, for a transaction totalling $1,114,218.56. Following the completion of the sale, the chairman now directly owns 27,644 shares of the company's stock, valued at $11,596,934.44. Learn More on Jeffrey M. Leiden's trading history.

Who are Vertex Pharmaceuticals' active insiders?

Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Vertex Pharmaceuticals?

During the last year, insiders at the pharmaceutical company sold shares 42 times. They sold a total of 161,940 shares worth more than $57,208,488.37. The most recent insider tranaction occured on February, 20th when EVP Ourania Tatsis sold 480 shares worth more than $201,979.20. Insiders at Vertex Pharmaceuticals own 0.3% of the company. Learn More about insider trades at Vertex Pharmaceuticals.

Information on this page was last updated on 2/20/2024.

Jeffrey M. Leiden Insider Trading History at Vertex Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/12/2024Sell2,656$419.51$1,114,218.5627,644View SEC Filing Icon  
1/8/2024Sell6,648$419.07$2,785,977.362,423View SEC Filing Icon  
10/16/2023Sell12,962$374.00$4,847,788.0022,425View SEC Filing Icon  
5/8/2023Sell1,125$349.00$392,625.0035,387View SEC Filing Icon  
5/5/2023Sell879$349.56$307,263.2436,512View SEC Filing Icon  
5/2/2023Sell6,450$349.89$2,256,790.5041,899View SEC Filing Icon  
7/25/2022Sell132,079$281.38$37,164,389.022,423View SEC Filing Icon  
4/13/2022Sell15,789$289.04$4,563,652.5674,160View SEC Filing Icon  
6/30/2020Sell32,792$286.15$9,383,430.8029,252View SEC Filing Icon  
5/12/2020Sell94,370$283.47$26,751,063.9065,036View SEC Filing Icon  
5/5/2020Sell94,372$269.94$25,474,777.6876,707View SEC Filing Icon  
2/25/2020Sell10,550$233.46$2,463,003.00103,131View SEC Filing Icon  
2/18/2020Sell11,685$243.52$2,845,531.20123,226View SEC Filing Icon  
11/18/2019Sell9,434$216.75$2,044,819.50170,378View SEC Filing Icon  
11/1/2019Sell96,822$200.02$19,366,336.44115,166View SEC Filing Icon  
10/22/2019Sell107,831$190.00$20,487,890.00178,707View SEC Filing Icon  
6/18/2019Sell56,030$175.39$9,827,101.70162,317View SEC Filing Icon  
5/24/2019Sell113,432$175.10$19,861,943.20219,719View SEC Filing Icon  
5/6/2019Sell33,058$175.01$5,785,480.58136,953View SEC Filing Icon  
5/1/2019Sell10,480$175.08$1,834,838.40View SEC Filing Icon  
2/19/2019Sell20,997$186.98$3,926,019.06110,095View SEC Filing Icon  
2/11/2019Sell111,431$180.24$20,084,323.44223,916View SEC Filing Icon  
2/4/2019Sell32,250$186.35$6,009,787.50155,815View SEC Filing Icon  
6/22/2018Sell140,211$160.00$22,433,760.00297,260View SEC Filing Icon  
2/12/2018Sell23,905$150.83$3,605,591.15208,463View SEC Filing Icon  
1/16/2018Sell99,563$156.99$15,630,395.37176,747View SEC Filing Icon  
12/11/2017Sell125,000$141.35$17,668,750.00237,407View SEC Filing Icon  
7/31/2017Sell11,063$152.81$1,690,537.03268,455View SEC Filing Icon  
7/21/2017Sell216,624$160.96$34,867,799.04400,266View SEC Filing Icon  
6/2/2017Sell147,101$129.50$19,049,579.50312,142View SEC Filing Icon  
4/28/2017Sell157,200$119.50$18,785,400.00395,152View SEC Filing Icon  
2/3/2016Sell9,834$90.82$893,123.88261,885View SEC Filing Icon  
12/15/2014Sell50,017$114.97$5,750,454.49View SEC Filing Icon  
9/30/2014Sell200,000$112.69$22,538,000.00View SEC Filing Icon  
See Full Table

Jeffrey M. Leiden Buying and Selling Activity at Vertex Pharmaceuticals

This chart shows Jeffrey M Leiden's buying and selling at Vertex Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vertex Pharmaceuticals Company Overview

Vertex Pharmaceuticals logo
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $430.11
Low: $429.07
High: $434.50

50 Day Range

MA: $421.68
Low: $400.25
High: $446.08

2 Week Range

Now: $430.11
Low: $283.60
High: $448.40

Volume

749,800 shs

Average Volume

1,516,468 shs

Market Capitalization

$111.10 billion

P/E Ratio

30.97

Dividend Yield

N/A

Beta

0.36